The executive of a private health group has expressed disappointment that a planned inquiry into South Africa’s private healthcare market by the Competition Commission will not also umbrella the pharmaceutical sector. Netcare CEO Richard Friedland offered the remarks on Monday, noting that consumers pay “40 percent more” for drugs in South Africa. The Commission’s planned review of the healthcare market will bring private hospitals and medical schemes under a close watch but appears to let the pharmaceutical sector off the hook under the argument that pharmaceutical prices are already regulated. Further, Friedland said the allowance of parallel imports of drugs could help lower costs for consumers. Netcare is currently the nation’s third-largest private hospital group.
Featured News
Perkins Coie Adds Former DOJ Antitrust Leader as Partner in Washington
Jan 22, 2026 by
CPI
Ryanair Boss Dismisses Musk’s Buyout as Starlink Feud Escalates
Jan 22, 2026 by
CPI
Paramount Extends Warner Bros Bid as Netflix Rivalry Heats Up
Jan 22, 2026 by
CPI
South Korea Breaks New Ground With Landmark AI Law
Jan 22, 2026 by
CPI
NYDFS Warns Banks They Can’t Outsource Vendor Risk
Jan 22, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Recidivism
Jan 21, 2026 by
CPI
Recidivism, Multiple Offending, and Serial Offending in Antitrust
Jan 21, 2026 by
Gregory Werden
Antitrust Recidivism: Why Repeat Cases Appear, and Why True Reoffending Is Rare in the United States
Jan 21, 2026 by
Lisa M. Phelan, Megan S. Golden, Adrienne Irmer & Nina Worth
99 Antitrust Problems – Is Recidivism One?
Jan 21, 2026 by
Brian A. Ratner & Kartik S. Madiraju
Holding A Cat by the Tail: A View of Cartel Recidivism in U.S. Antitrust Enforcement
Jan 21, 2026 by
Mark Rosman & KaDee L. Ru